Disease:
over-anticoagulation

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2C9 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *5 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *11 N/A N/A N/A
No VIP available No VIP available VA VKORC1 *1 N/A N/A N/A
No VIP available No VIP available VA VKORC1 *2 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1057910 NC_000010.10:g.96741053A=, NC_000010.10:g.96741053A>C, NC_000010.11:g.94981296A=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NG_008385.1:g.47639A>C, NM_000771.3:c.1075A=, NM_000771.3:c.1075A>C, NP_000762.2:p.Ile359=, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, XM_005269575.1:c.1075A>C, XP_005269632.1:p.Ile359=, XP_005269632.1:p.Ile359Leu, rs17847042, rs3198471, rs61212474
A > C
SNP
I359L
No VIP available No Clinical Annotations available VA
rs2108622 NC_000019.10:g.15879621C>T, NC_000019.9:g.15990431C>T, NG_007971.2:g.23454G>A, NM_001082.4:c.1297G>A, NP_001073.3:p.Val433Met, rs116975254, rs52819608, rs57319528
C > T
SNP
V433M
No VIP available No Clinical Annotations available VA
rs3814637 NC_000010.10:g.96521045C>T, NC_000010.11:g.94761288C>T, NG_008384.2:g.3583C>T, NM_000769.2:c.-1418C>T, rs11565103, rs117910415, rs17878465, rs58858251
C > G
C > T
SNP
No VIP available No Clinical Annotations available VA
rs6046 NC_000013.10:g.113773159G>A, NC_000013.11:g.113118845G>A, NG_009258.1:g.1047G>A, NG_009262.1:g.18055G>A, NM_000131.4:c.1238G>A, NM_001267554.1:c.986G>A, NM_019616.3:c.1172G>A, NP_000122.1:p.Arg413Gln, NP_001254483.1:p.Arg329Gln, NP_062562.1:p.Arg391Gln, NR_051961.1:n.1259G>A, XM_006719963.2:c.1031G>A, XM_011537474.1:c.1280G>A, XM_011537475.1:c.1094G>A, XM_011537476.1:c.932G>A, XM_011537477.1:c.1241G>A, XP_006720026.1:p.Arg344Gln, XP_011535776.1:p.Arg427Gln, XP_011535777.1:p.Arg365Gln, XP_011535778.1:p.Arg311Gln, XP_011535779.1:p.Arg414Gln, rs112274850, rs36209568, rs532977
G > -
G > A
SNP
R413Q
No VIP available CA VA
rs9923231 NC_000016.10:g.31096368C=, NC_000016.10:g.31096368C>T, NC_000016.9:g.31107689C=, NC_000016.9:g.31107689C>T, NG_011564.1:g.3588G=, NG_011564.1:g.3588G>A, NM_001311311.1:c.-1639G=, NM_001311311.1:c.-1639G>A, NM_024006.5:c.-1639G=, NM_024006.5:c.-1639G>A, NM_206824.2:c.-1639G=, NM_206824.2:c.-1639G>A, XM_005255568.1:c.-1639G=, XM_005255568.1:c.-1639G>A, XM_011545943.1:c.-1639G=, XM_011545943.1:c.-1639G>A, XM_011545944.1:c.-1252G=, XM_011545944.1:c.-1252G>A, XM_011545945.1:c.-1252G=, XM_011545945.1:c.-1252G>A, XR_243303.1:n.-990G=, XR_243303.1:n.-990G>A, XR_950848.1:n.-31G=, XR_950848.1:n.-31G>A, rs117572127, rs17878363, rs60511154
C > A
C > G
C > T
SNP
No VIP available No Clinical Annotations available VA
rs9934438 NC_000016.10:g.31093557G>A, NC_000016.9:g.31104878G>A, NG_011564.1:g.6399C>T, NM_001311311.1:c.174-136C>T, NM_024006.5:c.174-136C>T, NM_206824.2:c.173+1000C>T, XM_005255568.1:c.174-136C>T, XM_011545943.1:c.174-136C>T, XM_011545944.1:c.174-136C>T, XM_011545945.1:c.173+1000C>T, XR_243303.1:n.823-236C>T, XR_950848.1:n.962-136C>T, rs17641219
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names: 
PharmGKB Accession Id: PA166123298

Curated Information ?

Curated Information ?

No related diseases are available

Publications related to over-anticoagulation: 46

No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients. Medicine. 2016. Misasi Silvia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users. Pharmacotherapy. 2016. Shendre Aditi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome medicine. 2016. Bourgeois Stephane, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy. International journal of clinical pharmacology and therapeutics. 2015. Mandic Dario, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis. Journal of Korean medical science. 2014. Lee Ji Eun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. Puerto Rico health sciences journal. 2014. Valentín Isa I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics role in the safety of acenocoumarol therapy. Thrombosis and haemostasis. 2014. Jiménez-Varo E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics. 2014. Cerezo-Manchado Juan Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation. Pharmacological reports : PR. 2014. Nahar Risha, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population. European journal of pharmacology. 2013. Gaikwad Tejasvita, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. European journal of clinical pharmacology. 2013. Santos Paulo Caleb Junior Lima, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. International journal of hematology. 2012. Ma Cong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. Journal of thrombosis and haemostasis : JTH. 2012. Verhoef T I, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VKORC1 and CYP2C9 genotype is associated with over-anticoagulation during initiation of warfarin therapy in children. Journal of thrombosis and haemostasis : JTH. 2012. Biss T T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. British journal of haematology. 2012. Lund Kirstin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers. European journal of clinical pharmacology. 2012. Mlynarsky Liat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. Journal of thrombosis and haemostasis : JTH. 2012. Verhoef T I, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. European journal of clinical pharmacology. 2011. Zhong Shi-Long, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. Thrombosis and haemostasis. 2011. Luxembourg Baete, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease. Annals of clinical and laboratory science. 2011. Moon Hee-Won, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response. European journal of clinical pharmacology. 2010. Molden Espen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clinical pharmacology and therapeutics. 2010. Pautas E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. Journal of thrombosis and haemostasis : JTH. 2010. Ferder N S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenetics and genomics. 2009. Jorgensen Andrea L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood. 2009. Li Chun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clinical pharmacology and therapeutics. 2009. Teichert M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009. Wadelius Mia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood cells, molecules & diseases. 2009. Limdi N A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics. 2008. Spreafico Marta, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thrombosis and haemostasis. 2008. Meckley Lisa M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics. 2008. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. Pediatric blood & cancer. 2008. Ruud Ellen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007. Anderson Jeffrey L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clinical pharmacology and therapeutics. 2007. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics. 2007. Kealey Carmel, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clinical pharmacology and therapeutics. 2006. Schalekamp Tom, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clinical pharmacology and therapeutics. 2004. Schalekamp Tom, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clinical pharmacology and therapeutics. 2004. Schalekamp Tom, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clinical pharmacology and therapeutics. 2004. Peyvandi Flora, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics. 2004. Visser Loes E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2003. André-Kerneïs Elisabeth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic and environmental risk factors for oral anticoagulant overdose. European journal of clinical pharmacology. 2003. Verstuyft C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica. 2002. Tàssies Dolors, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA : the journal of the American Medical Association. 2002. Higashi Mitchell K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics. 2001. Verstuyft C, et al. PubMed